These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 15314658)

  • 1. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
    Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
    PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis.
    Ruddell A; Kelly-Spratt KS; Furuya M; Parghi SS; Kemp CJ
    Oncogene; 2008 May; 27(22):3145-55. PubMed ID: 18059331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
    Lin AW; Lowe SW
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.
    Tolbert D; Lu X; Yin C; Tantama M; Van Dyke T
    Mol Cell Biol; 2002 Jan; 22(1):370-7. PubMed ID: 11739748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
    Russell JL; Weaks RL; Berton TR; Johnson DG
    Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor spectrum in ARF-deficient mice.
    Kamijo T; Bodner S; van de Kamp E; Randle DH; Sherr CJ
    Cancer Res; 1999 May; 59(9):2217-22. PubMed ID: 10232611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
    Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
    Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
    Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA
    Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5947-52. PubMed ID: 16585505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.
    Inoue K; Wen R; Rehg JE; Adachi M; Cleveland JL; Roussel MF; Sherr CJ
    Genes Dev; 2000 Jul; 14(14):1797-809. PubMed ID: 10898794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition.
    Macdonald FH; Yao D; Quinn JA; Greenhalgh DA
    Oncogene; 2014 Aug; 33(32):4132-43. PubMed ID: 24037529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice.
    Eischen CM; Rehg JE; Korsmeyer SJ; Cleveland JL
    Cancer Res; 2002 Apr; 62(7):2184-91. PubMed ID: 11929842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent genetic control of early and late stages of chemically induced skin tumors in a cross of a Japanese wild-derived inbred mouse strain, MSM/Ms.
    Okumura K; Sato M; Saito M; Miura I; Wakana S; Mao JH; Miyasaka Y; Kominami R; Wakabayashi Y
    Carcinogenesis; 2012 Nov; 33(11):2260-8. PubMed ID: 22843548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
    Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K
    Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype.
    King D; Yang G; Thompson MA; Hiebert SW
    Oncogene; 2002 Jul; 21(32):4978-82. PubMed ID: 12118376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p19ARF-induced p53-independent apoptosis largely occurs through BAX.
    Suzuki H; Kurita M; Mizumoto K; Nishimoto I; Ogata E; Matsuoka M
    Biochem Biophys Res Commun; 2003 Dec; 312(4):1273-7. PubMed ID: 14652011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.
    Bardeesy N; Morgan J; Sinha M; Signoretti S; Srivastava S; Loda M; Merlino G; DePinho RA
    Mol Cell Biol; 2002 Jan; 22(2):635-43. PubMed ID: 11756558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of function in the mouse model of a recurrent mutation p53
    Zhao L; Wang B; Zhao X; Wu X; Zhang Q; Wei C; Shi M; Li Y; Tang W; Zhang J; Yang J; Singh SK; Jia S; Luo Y
    Mol Carcinog; 2018 Feb; 57(2):147-158. PubMed ID: 28949402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest.
    Rowland BD; Denissov SG; Douma S; Stunnenberg HG; Bernards R; Peeper DS
    Cancer Cell; 2002 Jul; 2(1):55-65. PubMed ID: 12150825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities.
    Guo F; Gao Y; Wang L; Zheng Y
    J Biol Chem; 2003 Apr; 278(16):14414-9. PubMed ID: 12578823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.